Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

NIH 4OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Hemangiosarcoma 1Gliosarcoma 1Glioblastoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Cyclophosphamide 109Bevacizumab 97Magnetic Resonance Spectroscopy 91Specimen Handling 88Biopsy 75Paclitaxel 64fludarabine phosphate 62Immunoglobulin G 61Disulfides 61Carboplatin 58Taxes 53Cisplatin 52Doxorubicin 51fludarabine 49Sorafenib 46Radiation 46aldesleukin 45Radiotherapy 45Prednisone 45Etoposide 45Vincristine 41Sirolimus 40Platinum 40Bortezomib 38Rituximab 371,2-diaminocyclohexaneplatinum II citrate 37Nivolumab 36Cytarabine 35temsirolimus 34Vorinostat 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Has results × trebananib × Clear all
NCT01609790 2022-07-21

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

National Cancer Institute (NCI)

Phase 2 Completed
137 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT01664182 2022-06-07

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 13 charts
Genitourinary

Carcinoma, Renal Cell

NCT01553188 2019-03-05

AMG 386 and Abiraterone for Advanced Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
36 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT01623869 2015-10-19

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 6 charts
Sarcoma

Hemangiosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡